ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again
The trial-level analysis suggests a dose-response relationship between exposure to angiotensin receptor blockers and the risk for cancer, reawakening previous questions on this issue. Medscape Medical News …read more